Optimi Health

At the H.C. Wainwright conference, Optimi Health said it is already supplying commercially produced psilocybin and MDMA capsules in Australia and through Canada’s Special Access Program, claiming a rare market entry. Production takes place in a fully integrated facility in Princeton with approvals from Health Canada and an FDA site number, which would enable rapid market entry if the U.S. reclassifies these substances. Optimi has raised $30 million to date, sees its main competition among synthetic developers, expects regulatory catalysts in the U.S. and Canada, and plans to launch an ibogaine product by the end of 2026. » Więcej na de.investing.com

Optimi Health has received Health Canada approval for a phase II study of psilocybin-assisted treatment for major depression. Up to 200 participants are planned across multiple sites in Canada, with a start in the first half of 2027 and dosing completed by the end of 2027. The study will assess the safety and efficacy of a single supervised dose of natural psilocybin, with the primary endpoint being change on the Montgomery-Åsberg Depression Rating Scale. Optimi will supply the psilocybin from its GMP-certified facility, will retain the study data, and says funding is secured with existing cash resources. » Więcej na de.investing.com

Optimi Health released results for the quarter ended 31 March 2026. Revenue rose year-on-year by 66.67% and amounted most recently to 0.1 million CAD versus 0.1 million CAD in the same quarter last year (rounded figures). » Więcej na finanzen.net

Optimi Health placed 2.4 million common shares at $6.25 each and raised gross proceeds of $15 million. The shares are traded on the Nasdaq Capital Market under the ticker OPTH; Joseph Gunnar & Co. acted as sole book-running manager. The underwriter was granted 96,000 warrants to purchase shares at $7.50 until May 2031. The capital is intended to strengthen the balance sheet and provide working capital for growth, while the company still has a small market capitalization and financial metrics rated as "weak," and the stock is down about 69% year-to-date. » Więcej na de.investing.com